



Submitted by:
Kiitan Babalola, PharmD
Manager, Global Medical Information
Celgene Corporation
86 Morris Avenue
Summit NJ, 07901
Ph: 908-679-7870
Email: obabalola@celgene.com
Date of Request: July 14, 2016

Dear NCCN Acute Myeloid Leukemia Panel:

On behalf of Celgene Corporation, we respectfully request that the NCCN Guidelines Panel for Acute Myeloid Leukemia (AML) review the enclosed information regarding the clinical importance of isocitrate dehydrogenase (IDH) testing for AML patients.

Specific Changes: Update the discussion section (pages MS-3 to MS-12) to include additional data supporting the prognostic impact of IDH mutations in AML patients. In addition, we request an update to the footnotes on pages AML-10 (ggg) and AML-14 (www) to include molecular profiling of IDH mutations as it may assist with the selection of appropriate clinical trials.

Rationale: As stated in the current AML NCCN Guidelines, Version 2.2016, the evaluation of several molecular markers may be important for risk assessment and prognostication, and may also guide treatment decisions (MS-3). The recently published 2016 Revision to the World Health Organization (WHO) Classification of Myeloid Neoplasms and Acute Leukemia has included IDH1 and IDH2 into the supplemental table for molecular genetic alterations affecting clinical outcome of AML patients in specific cytogenetic groups.^{1-2,6,8}

Additionally, there are several ongoing clinical trials exploring the use of novel agents for AML patients harboring IDH mutations further underscoring the importance of molecular profiling to guide clinical trial selection. Information pertaining to ongoing clinical trials can be accessed on www.clinicaltrials.gov and via the following hyperlinks: [NCT02632708](https://clinicaltrials.gov/ct2/show/study/NCT02632708), [NCT02074839](https://clinicaltrials.gov/ct2/show/study/NCT02074839), [NCT02719574](https://clinicaltrials.gov/ct2/show/study/NCT02719574), [NCT02492737](https://clinicaltrials.gov/ct2/show/study/NCT02492737), [NCT02677922](https://clinicaltrials.gov/ct2/show/study/NCT02677922), [NCT02283190](https://clinicaltrials.gov/ct2/show/study/NCT02283190), [NCT01915498](https://clinicaltrials.gov/ct2/show/study/NCT01915498), [NCT02381886](https://clinicaltrials.gov/ct2/show/study/NCT02381886), [NCT02577406](https://clinicaltrials.gov/ct2/show/study/NCT02577406).

The 2016 Revision to the WHO Classification of Myeloid Neoplasms and Acute Leukemia as well as the following articles evaluating the impact of IDH mutations in AML in support of these proposed changes are enclosed for your review.²⁻¹² Several studies have demonstrated poorer outcomes in patients with mutant IDH compared to patients without IDH mutations.^{2,4,6-7,10-11} Your consideration of this submission is greatly appreciated.

References:

1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood*. 2016;127(20):2391-405. <http://www.ncbi.nlm.nih.gov/pubmed/27069254>.
2. Boissel N, Nibourel O, Renneville A, et al. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. *J Clin Oncol*. 2010;28(23):3717-23. <http://www.ncbi.nlm.nih.gov/pubmed/20625116>.
3. Paschka P, Schlenk RF, Weber D, et al. Outcome of Patients with Refractory or Relapsed AML with IDH1 and IDH2 Mutations After Conventional Salvage Therapy: A Study of the German-Austrian AML Study Group (AMLSG) [Oral]. Oral presented at: 21st Congress of the European Hematology Association (EHA); June 9-12, 2016; Copenhagen, Denmark.
4. Aref S, El Kamel Areida S, Abdel Aal MF, et al. Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients. *Clin Lymphoma Myeloma Leuk*. 2015;15(9):550-5. <http://www.ncbi.nlm.nih.gov/pubmed/26189213>.
5. DiNardo CD, Ravandi F, Agresta S, et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. *Am J Hematol*. 2015;90(8):732-6. <http://www.ncbi.nlm.nih.gov/pubmed/26016821>.
6. Nomdedeu J, Hoyos M, Carricondo M, et al. Adverse impact of IDH1 and IDH2 mutations in primary AML: experience of the Spanish CETLAM group. *Leuk Res*. 2012;36(8):990-7. <http://www.ncbi.nlm.nih.gov/pubmed/22520341>.
7. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. *N Engl J Med*. 2016;374(23):2209-21. <http://www.ncbi.nlm.nih.gov/pubmed/27276561>.
8. Thol F, Damm F, Wagner K, et al. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. *Blood*. 2010;116(4):614-6. <http://www.ncbi.nlm.nih.gov/pubmed/20421455>.
9. Wagner K, Damm F, Gohring G, et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. *J Clin Oncol*. 2010;28(14):2356-64. <http://www.ncbi.nlm.nih.gov/pubmed/20368538>.
10. Yamaguchi S, Iwanaga E, Tokunaga K, et al. IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation. *Eur J Haematol*. 2014;92(6):471-7. <http://www.ncbi.nlm.nih.gov/pubmed/24443894>.
11. Zhou K-G, Jiang L-J, Shang Z, Wang J, Huang L, Zhou J-F. Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis. *Leuk Lymphoma*. 2012;53(12):2423-9. <http://www.ncbi.nlm.nih.gov/pubmed/22616558>.
12. Green CL, Evans CM, Zhao L, et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. *Blood*. 2011;118(2):409-12. <http://www.ncbi.nlm.nih.gov/pubmed/21596855>.

Sincerely,



Kiitan Babalola, PharmD
Manager, Global Medical Information



Mary Sugrue, MD, PhD
Executive Director, US Medical Affairs Disease Lead-MDS, AML